About Us

We believe the cannabis plant has untapped efficacious agility and will disrupt Western medicine; and we believe medical breakthroughs will soon shatter conventional wisdom.

Integrity matters; CB1 Capital was built with the foundational constructs of honesty, trust and respect and our partners, employees and advisors are held to the highest standard of conduct and operational diligence.

This platform was set up to educate and inform; we believe this is the next generation of impact investing and our mission is to effect positive change through cannabinoid wellness.


It’s not about getting high; it’s about getting well.®


Our Team


Todd Harrison

Todd Harrison is the Founding Partner of CB1 and our Chief Investment Officer. Todd has spent almost three decades on Wall Street managing risk and researching financial market strategies. His institutional experience includes Morgan Stanley Global Equity Derivatives (VP), The Galleon Group (MD-Derivatives), and Cramer, Berkowitz LLC (President and Head of Trading).

Todd was also the Founder and CEO of Minyanville Media, Inc., an Emmy Award winning financial media company that covered global markets in real-time, developed, and licensed investment content to broker-dealers, and wrote real-time content that enabled millions of traders and investors to make more informed financial decisions. He oversaw all operating segments, enterprise relationships, dot.com properties, investment products and newsletters, gaming platforms, production studios and events.

Todd is also the founder & President of The Ruby Peck Foundation for Children’s Education, a member of the Young Presidents’ Organization (YPO) and he serves on the Advisory Board of the Nassau County Police Department Foundation. His first book, The Other Side of Wall Street, was published in 2011 by FT Press, and he received two Emmy Awards from The National Academy of Television Arts & Sciences.

He has been active in the research of financial market learning tendencies among college students, and was a contributing author to “ Threat, Intimidation, and Student Financial Market Knowledge: An Empirical Study,” published in the Journal of Education for Business.

Mr. Harrison has appeared on CNBC, FOX, FOX Business, MSNBC and Bloomberg as a financial authority and has been quoted and covered in The New York Times, The Wall Street Journal, BusinessWeek, Worth, Fortune, Forbes, Barron’s, Dow Jones MarketWatch, New York Magazine and Canada’s National Post. He was featured in the 20th Anniversary documentary of Oliver Stone’s Wall Street and the 2013 documentary, Money for Nothing: Inside the Federal Reserve; he was the international spokesman for eSignal, a division of IDC, from 2012-2014. He has a Bachelor of Science degree in Finance from Syracuse University.



Loren DeFalco

Loren DeFalco, CFP, is a Partner of CB1 and our Head of Research. Loren cured himself of epileptic seizures through a regime of CBD and cannabinoids nine years ago and continued to research ECS through medical journals and scientific developments. His intimate understanding of the ECS system and nutraceutical arena makes him an ideal choice to lead research efforts.

Prior to joining CB1, Loren was President of LAD Capital, Inc., a Vice President and financial representative at HSBC, and a Vice President of Financial Planning at MetLife Resources, after starting his career as a financial representative at Northwestern Mutual Financial Network. He has a Bachelor of Science in Business Administration degree from Long Island University.

I’ve spent the better part of my time since 2008 learning everything I could about the endocannabinoid system. I was driven to this material in search of a solution to my own health issues that I could not find a solution to, as the prescription medicine I was being prescribed was not working for my conditions.

Loren’s Story

In 2008, I had a massive seizure at the airport while waiting curbside for my ride home after a business trip. I woke up in an ambulance and had no idea where I was or where I had come from. It was quite scary. I went to a neurologist who ran tests on me. I was told that I had a “seizure disorder” and would need to take anti-seizure drugs or I would not be allowed to drive my car.

This was all very disturbing as I felt broken. The medication began to take its toll on me right away and the side effects were debilitating. The solution I was provided for the side effects of the medication was…MORE medication. I ended up taking five different prescription drugs that caused my body to break down even more to the point that I was no longer able to work.

I decided that it was time to take matters into my own hands and I started to research to find alternate ways of handling my new situation. This is when I came across the endocannabinoid system. My discovery was nothing short of revolutionary for my mind and body. I started to learn how diet and cannabinoids influenced disease in the body and completely changed my lifestyle. I started on a diet that was based on making sure I was balancing the omega 6 and omega 3 levels in my body as well as ingesting cannabinoids through hemp plant seeds and other sources.

Six months after I started my new lifestyle, focusing on the endocannabinoid system, I was cleared by my neurologist after my EEG showed no more seizure activity in my brain. Finally, I was able to shed all of my prescription drugs. Not only did my seizures stop, but I started to experience relief from other physical issues that I had been dealing with, such as sleeping issues and arthritic knee pain. This was amazing to me and I strived to learn more about this system that I had never heard of before and that had only been recently discovered.



Jon Tyras

Jon Tyras is a Partner of CB1 and our Chief Operating Officer, Chief Financial Officer and Chief Compliance Officer. Jon has spent over 20 years in the industry. He was most recently the Chief Financial Officer and General Counsel of the $15 billion public securities platform of Brookfield Asset Management, a leading global alternative asset manager with approximately $250 billion in AUM.

Before his 10+ years with Brookfield, Jon was a capital markets attorney with Paul Hastings LLP for eight years. Prior to his admission to the New York Bar, he spent four years with Ernst & Young, where he was a Certified Public Accountant. He has Bachelor of Science degrees in Finance and Accounting, cum laude, from Georgetown University and a Juris Doctor degree from the University of Pennsylvania Law School.



Josh Felker

Josh Felker is a Research Analyst at CB1 and our resident Canadian market reference. Josh began covering the Canadian legalization initiative in November ’16 when the Canadian Task Force report signaled a real-world chance of legalization occurring. He has written extensively for FelkerInvesting.com before joining CB1 Capital, consistently reaching the top pages of Reddit/Google for articles regarding the valuation of Canadian Licensed Producers. Josh is CSC accredited and has maintained a strict adherence to the Buffett/Munger/Klarrman-style of security analysis.



Andrew Pfeffer

Andrew is a Senior Trader at CB1 who works directly with the investment team. Andrew has been in equities for over 20 years. After spending some time on the buy side, Andrew spent 18 years in trading at Virtu Financial and its predecessor firms, a leading market maker and liquidity provider, and was Head of Trading for the Healthcare and Biotech sectors. He has a Bachelor of Arts degree from Cornell University.



Grace Livingston

Grace Livingston is our Investor Relations professional and works directly with CB1 senior management. Since starting her career at Morgan Stanley in 2012, Grace has built an extensive network of institutional investors coupled with buy and sell side relationships. Over the past five years, she has consulted for public microcap companies, family offices and institutional research platforms on sales, marketing, investor relations, public relations and capital raising. Grace has a Bachelor of Arts degree from the University of Alabama. 


Our Advisory Board


Dr. Ethan Russo

Board Certified Neurologist, psychopharmacology researcher; Director of Research & Development, International Cannabis and Cannabinoid Institute (ICCI), former Senior Medical Advisor, GW Pharmaceuticals; former Medical Director, PHYTECS.


Dr. Julie Holland

Psychiatrist and psychopharmacologist, Author of the bestsellers “Weekends at Bellevue” and “Moody Bitches”, editor of “The Pot Book: A Complete Guide to Cannabis”, medical monitor for a clinical study examining the efficacy of using cannabis in the treatment of Post Traumatic Stress Disorder in veterans.


Lorne Gertner

Chairman of HG2 Capital Corp, CEO of Hill & Gertner Capital Group; Co-Founder, The Cronos Group; Director, Emblem Corp.; Co-Founder & Chairman Tokyo Smoke; Investment Partner and Director, Green Acre Capital.


Gov. Gary Johnson

Twenty-ninth governor of New Mexico, two-time Presidential candidate. Founder, Big J Enterprises; Former CEO of Cannabis Sativa, Inc.


Dave Charnick

Subject Matter Expert, Founder, Kalyx Development Inc. and Special Advisor, Cannabis Benchmarks, a division of New Leaf Data Sciences.